Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Study Overview: Bristol-Myers Squibb, in collaboration with Janssen Research & Development, has completed a Phase 1 clinical study titled ‘A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms.’ The study aimed to evaluate the safety of the neoantigen vaccine VAC85135 when administered with ipilimumab in patients with myeloproliferative neoplasms (MPNs), a group of blood cancers. This research is significant as it explores new treatment avenues for MPNs, potentially improving patient outcomes.
Intervention/Treatment: The study tested two interventions: VAC85135, a biological neoantigen vaccine administered via intramuscular injection, and ipilimumab, a drug given through intravenous infusion. These treatments are intended to work together to enhance the immune response against cancer cells in MPN patients.
Study Design: The study was interventional, non-randomized, and followed a sequential intervention model. It was unmasked, meaning both researchers and participants knew which treatments were being administered. The primary purpose was treatment-focused, aiming to assess the safety of the interventions.
Study Timeline: The study began on July 21, 2022, and was last updated on July 17, 2025. These dates are crucial as they provide a timeline for the study’s progression and the latest updates on its findings.
Market Implications: The completion of this study could influence Bristol-Myers Squibb’s stock performance positively by showcasing their commitment to innovative cancer treatments. Successful results may boost investor confidence and position the company favorably against competitors in the oncology sector. As the study progresses, it could also impact the broader market by setting new standards for MPN treatment.
The study is completed, with further details available on the ClinicalTrials portal.